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Abstract
Introduction Fibrodysplasia ossificans progressiva (FOP)
is a rare disorder characterized by episodes of acute pain
and heterotopic ossification of soft tissue, and progres-
sively limited physical function and social participation.
Objective We aimed to determine the impact of FOP on
quality of life, specifying areas or dimensions most
affected.
Materials and methods This was a transverse observa-
tional study; patients with FOP were assessed using the
Short Form 36. Questionnaire results were obtained using
Quality Metric software and analyzed using frequency
distribution, percentages and measures of central tendency.
Results Eight patients, mean age 30.2 years, were inclu-
ded. The physical dimension was the most affected, with an
average of 25.5 points. The most representative items were
impaired function and physical role. Physical pain was
found with an average of 44.5 points. The best scores were
reported in the areas of emotional role and mental health,
with an average of 79 and 76 respectively.
Conclusions FOP is a severely disabling disease, gener-
ating a significant deterioration in quality of life secondary
to progressive deterioration in physical abilities. The
findings of this study demonstrate good self-rated health of
participants.
Keywords Fibrodysplasia ossificans progressiva 
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Introduction
Fibrodysplasia ossificans progressiva (FOP), also known as
myositis ossificans progressiva, is a rare disorder with an
estimated incidence of 1 in 2,000,000 [1]. It is the most
severe cause of disabling ossification disease in humans
[2]. The inheritance is autosomal dominant, though most
cases are de novo mutations [3]. The etiological basis is
presumed to be a deregulation of bone morphogenetic
proteins, due to an alteration in the ACVR1 gene [4].
The clinical picture is characterized by episodes of acute
pain, followed by the appearance of subcutaneous nodules
(flare-ups) that evolve to ossify the soft tissues (muscles,
ligaments, fascia, tendons), with a cephalo-caudal pattern,
starting in the dorsal, axial, cephalic and proximal areas,
progressing to ventral, appendicular, caudal and distal tis-
sues [5]. The progression of this cascade leads to multiple
and progressive ossification forming an exoskeleton in the
patient [6].
The cycle trigger may be low-energy trauma, intra-
muscular injections, simple contusions or viral infections,
among other stress factors [7].
The diagnosis is purely clinical and pivot data is con-
sidered to be symphalangism with shortening and hallux
varus [8], as shown in Figs. 1, 2 and 3.
Misdiagnosis is often the rule because of the very low
incidence of this disease. Patients generally undergo
unnecessary procedures (biopsies, osteotomies,
chemotherapy) that can lead to permanent disability in up
to 50 % [9], accelerating the emergence of new nodules
which ends in the cascade of nodules, ossification and
progressive limitation that leads to permanent ossifications
and disability [10] (Figs. 4, 5).
It is believed that the quality of life in patients with these
characteristics is poor [11]; however, there are no studies in
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this field due to the low incidence of FOP. Most of the
clinical papers published are case reports [12, 13].
There are in the literature different tools for assessing
quality of life and degree of disability in patients with
orthopedic disorders.
The Medical Outcomes Study 36-item Short Form (SF-
36) [14] is a generic questionnaire that calculates the
quality of life related to health in orthopedic and medical
conditions. It may be reliably self-administered by the
patient. It rates different aspects (physical functioning,
physical and emotional role, pain and emotional health) so
that the clinician can make an assessment for each domain
independently or in general.
The aim of this study is to determine the impact of FOP
on quality of life, describing the most affected areas, in
order to decide on palliative care for these patients, since
FOP is not yet a curable disease.
Fig. 1 Clinical image of the main suspect characteristic in FOP:
symphalangism with shortening and varus in toes
Fig. 2 Shortening of thumb or first toes is the first sign in the FOP
patient
Fig. 3 The varus and shortening in the same patient is caused by
aberrant proximal delta phalange in the first toe
Fig. 4 Characteristic pattern of ossification in FOP, showing pro-
gressive fusion of the cervical spine with decreasing range of
movement
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Materials and methods
A cross-sectional study was developed comprising eight
patients diagnosed with fibrodysplasia ossificans progres-
siva, maintaining contact or control in the Pediatric
Orthopedic service at the High Specialty Regional Hospital
in Bajio. All of them were of Latin American origin, so the
Validated Spanish version of the SF-36 clinical question-
naire was used to assess the quality of life. All the indi-
viduals were asked whether or not they would participate in
the study. All the forms were sent and the results compiled
electronically. Assistance was given by evaluator through
telephone or electronic monitoring.
The results of the questionnaires were obtained by
online software Quality Metric, scoring each item from 0
to 100. The weighted overall scores established standards
and physical and mental dimensions.
Data analysis of qualitative variables was by frequency
distribution and percentages. Quantitative variables were




Eight patients (six female and two male) were evaluated.
Their ages ranged from 16 to 43 years, with a mean of
30.2 years. The demographics of the eight patients are
summarized in Table 1. The values are broken down by
category in Table 2.
The age at definitive diagnosis of FOP ranged from 4 to
29 years (mean 17.6 years), but the onset of symptoms
started from 3 to 6 years in all patients with a cervical
tumor or lump resembling infarcted ganglia, which was
assumed in most cases to be a tumor. Only one of the
patients had an early FOP diagnosis (4 years old), while the
others were misdiagnosed with tumor, multiple ostheo-
chondromatosis or myositis. Six of them were subject to
more than four (range 4–16) invasive procedures (skin and
bone biopsies, osteotomies) until a definite diagnosis was
reached.
Tumor biopsy was performed in all eight patients, fol-
lowed by more ossified lesions leading to progressive
disability because of ossification, following a cephalo-
caudal and centrifugal pattern. Clinical features present at
birth in all patients were symphalangism of the great toe,
all were diagnosed as congenital hallux varus. No other
clinical or laboratory characteristic was present from birth.
At the time of the study, none of the patient had any
marfanoid habitus, since their heights ranged from 1.50 to
1.70 m (mean 1.60 m).
Since the gold standard for diagnosis are clinical and
radiographic features, only one of the patients had DNA
analysis to confirm the classical mutation. There is no
evidence that FOP patients have any increase in serum
bone markers (alkaline phosphatase, serum calcium, lactic
dehydrogenase, etc.) and these were not evaluated for this
study.
Fig. 5 Bony bridges between scapula and left humerus, the right
bridge developing. Ossification in the lowest right ribs
Table 1 Sociodemographic characteristics of the study sample,
N = 8













Elementary school 2 25
High school 3 37.5
College–University 3 37.5
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Functional results
Zero values were reported in two patients (34 and 43 years
old), as they use wheelchairs for mobility, reporting them-
selves as nearly fully dependent for feeding, self-cleaning
and transportation. The highest value in this category came
from a 26-year-old female who does not need any assistance
in walking. In no case did values reach the minimum mean
value for the normal population, which shows the severe
effect on physical function in FOP patients.
Regarding the pain scale, values ranged from 10 to 84
points. The lowest value (most pain) was from a 17-year-
old female who was going through an active phase of the
disease, followed by a 34-year-old male who has almost
full body immobility. The highest value (least pain) came
from a 32-year-old female who is fully functional and
ambulatory.
Emotional role does not seem to be affected. Every patient
showed a solid emotional status (except for a 17-year-old
female who was undergoing an active phase of the disease).
Mental health was not dependent on time from onset of
symptoms or years lived with this condition, since high
values were obtained in patients with more than 20 years of
the disease. The lowest score was from a single 30-year-old
male without any other external factor.
Individual values
Regarding the individual results, the best global score (85
points) was achieved from the individual with the highest
mental, emotional and social scores; this is mainly because
she is a very independent single woman who does not need
any assistance for activities of daily living.
The lowest score (27.4 points) was recorded in the
young female who was living through an active phase of
the disease, and was restricted in mobility and manifested
difficult pain control.
In the rest of the patients (all of them in a quiescent
phase of disease), the lowest global score was 27.6 points
in one individual with a worsening level of independence.
The worst outcome (in patients who were in a quiescent
phase of disease) was seen in one 28-year-old male who
has lived with the disease the longest (28 years from
beginning of symptoms).
Scores on the physical and mental dimensions are
summarized in Table 3.
It is noted that the physical dimension is themost affected,
presenting the worst scores with a mean of 25.5. The most
representative data show deterioration in function and
physical role. Pain is one of the primary characteristics of this
disease and was found with an average of 44.25 points.
Of the four main scales, representative examination of
mental health and social function had lower correlations. The
best scores were reported in the areas of emotional role and
mental healthwith an average of 79 and 76 points, respectively.
Discussion
There is poor functional outcome of patients with FOP
from severe mobility restriction as they progress in the
disease. It is to be expected that older patients show lower
Table 2 Descriptive
questionnaire by category in SF-
36
Results of SF-36 Patient no.
1 2 3 4 5 6 7 8
Physical function (PF) 0.0 55.0 35.0 5.0 40.0 35.0 35.0 0.0
Role physical (RP) 0.0 25.0 0.0 0.0 100.0 0.0 0.0 0.0
Body pain (BP) 12.0 41.0 62.0 10.0 72.0 41.0 32.0 84.0
General health (GH) 30.0 35.0 45.0 20.0 92.0 40.0 52.0 100.0
Vitality (VT) 60.0 60.0 60.0 50.0 90.0 80.0 25.0 65.0
Social function (SF) 50.0 37.5 62.5 25.0 100.0 37.5 37.5 75.0
Role emotional (RE) 100.0 100.0 100.0 33.3 100.0 100.0 0.0 100.0
Mental health (MH) 96.0 68.0 72.0 76.0 100.0 80.0 40.0 80.0
Mental health and emotional role are the most preserved values among FOP patients
Table 3 Summary of scores on
physical and mental dimension
SF-36
Summary scales Patient no.
1 2 3 4 5 6 7 8
Physical Component Summary (PCS) 8.5 29.3 26.5 14.2 41.9 22.5 32.7 28.9
Mental Summary Score(MCS) 68.4 51.7 57.7 49.8 68.3 60.1 30.2 64.1
The severe physical impairment of all participants is clear since the higest value (best result) must approach
100 points
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scores on function and physical role, and those who are
younger, even though they preserve more mobility, do not
have a high enough score to be considered independent
(maximum of 55 points in subject 2). One would expect
that with more progress in functional limitation all scales
would be affected; however, this did not occur in the
emotional role, where high scores persisted. It is note-
worthy that no patients were receiving psychological
therapy that helped them to accept or cope with their
situation.
Conclusion
FOP is an extremely rare disease; subjects who suffer from it
still undergo multiple procedures that aggravate their con-
dition before the correct diagnosis [15]. To date, there is no
treatment, and the only demonstrably effective medical
intervention is the application of high-dose steroids within
the first 24–36 h of the initial lesion (flare-up) [16]. Pro-
gression towards limiting basic activities and hygiene is so
severe that around 30 years old, most patients are confined to
a wheelchair with consequent burden and and strain on the
family, both socially and economically [17].
The mean life expectancy is 50–60 years as a result of
cardiopulmonary complications and severe malnutrition
[18].
To the best of our knowledge there is no other study on
the general functional status of patients with this disease.
The present study has several limitations, especially the
size of the sample; however, the low incidence of this
pathology makes a larger study difficult. Studies must be
larger and continue to spread knowledge of this disease to
avoid under-diagnosis and foster early recognition of these
patients, in order to avoid a rapid progression to depen-
dence in activities of daily living, since the quality of life in
patients with FOP is initially reduced by physical mobility.
Using data collection instruments that measure and
characterize the multidimensional health approach pro-
mises improvements in the doctor–patient relationship, so
that patients will have a new framework regarding their
health care providers, and the latter will be able to judge
the effectiveness of management of the population served.
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